StockNews.AI
VOR
StockNews.AI
4 hrs

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

1. Vor Biopharma announces late-breaking presentation at ACR Convergence 2025. 2. Clinical data for telitacicept in Sjögren's disease evaluated in Phase 3 study. 3. Telitacicept has gained approval for multiple indications in China. 4. No systemic therapies exist for Sjögren's disease, creating market potential. 5. Results may influence global Phase 3 approval for telitacicept's efficacy.

5m saved
Insight
Article

FAQ

Why Bullish?

Vor is presenting promising Phase 3 data, potentially boosting investor confidence. Strong clinical results can lead to stock price appreciation, similar to other biotech stocks post-positive trial results.

How important is it?

The clinical data presentation directly relates to telitacicept, influencing future demand and market perception. It also highlights unmet needs in Sjögren's disease treatment, increasing VOR's strategic importance.

Why Short Term?

The presentation at ACR Convergence is imminent, likely to impact stock Price in the short term. A successful presentation can lead to a rapid increase in interest and investment.

Related Companies

RemeGen Co., Ltd.
September 29, 2025 07:00 ET  | Source: Vor Biopharma BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois. Late-Breaking Presentation Details Abstract Title: Efficacy and Safety of Telitacicept in Patients with Sjögren's Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study Session: Late-Breaking Posters Date & Time: Tuesday, October 28th, 10:30 AM – 12:30 PM CT In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) for primary Sjögren’s disease, which will become telitacicept’s fourth approved indication in China. About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. About TelitaciceptTelitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a placebo adjusted 4.83-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) at 24 weeks, the primary endpoint of the trial. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia-Pacific to support potential approval in the United States, Europe, and Japan. About Sjögren’s Disease (formerly known as Sjögren’s Syndrome)Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Hallmark symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system. About one-third of patients develop significant extraglandular involvement, and the disease carries an elevated lymphoma risk, often leading to substantial impairment in daily life. One of the most common rheumatic autoimmune diseases, Sjögren’s remains underdiagnosed, with roughly half of cases unrecognized and women comprising the vast majority of patients. Despite its prevalence and burden, no systemic disease-modifying therapies exist; current care focuses on symptom management with incomplete relief. Media & Investor Contacts:Carl Mauchcmauch@vorbio.com Sarah Spencerinvestors@vorbio.com

Related News